Form 4: Nektar Therapeutics CEO Receives Stock Grant
Insider Transaction (Form 4)
Howard W Robin, President & CEO and a Director of Nektar Therapeutics, received 57,200 shares of common stock on July 24, 2026.
Summary
- Grant/award: acquired 57,200 Stock Option on July 24, 2026; holds 57,200 after (Direct).
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.
Insider Transactions
Howard W Robin — Director, Officer (President & CEO)
| Date | Transaction | Security | Shares | Price | Value | Held After |
|---|---|---|---|---|---|---|
| 2026-07-24 | Grant/award | Stock Option | 57,200 | — | — | 57,200 |
Key Dates
| Date | Description |
|---|---|
| 2026-07-24 | Grant/award (57,200 shares) |
Keywords
insider transaction, Form 4, NKTR, NEKTAR THERAPEUTICS, neutral, Howard W Robin
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.